ارسل ملاحظاتك

ارسل ملاحظاتك لنا







Assessment the Use of Anticoagulant in Prophylaxis after Orthopedic Surgery in Omdurman Teaching Hospital

المؤلف الرئيسي: ٍSoliman, Asgad Hassan (Author)
مؤلفين آخرين: Mohamed, Elnazeer Ibrahim (Advisor)
التاريخ الميلادي: 2018
موقع: أم درمان
الصفحات: 1 - 42
رقم MD: 1000629
نوع المحتوى: رسائل جامعية
اللغة: الإنجليزية
الدرجة العلمية: رسالة ماجستير
الجامعة: جامعة أم درمان الاسلامية
الكلية: كلية الصيدلة
الدولة: السودان
قواعد المعلومات: Dissertations
مواضيع:
رابط المحتوى:
صورة الغلاف QR قانون

عدد مرات التحميل

2

حفظ في:
المستخلص: Background: The rates of venous thromboembolism complications such as deep vein thrombosis and pulmonary embolism have been shown to be around 40-60% within 7 to 14 days following orthopaedic lower limb surgery without thromboprophylaxis. Objectives: This study was designed to assess the use of anticoagulant prophylaxis after orthopedic surgery in Omdurman teaching hospital at Khartoum locality. Method: A cross sectional descriptive case finding study was performed, on 100 patients selected randomly in Omdurman teaching hospital at Khartoum state between December 2017 and January 2018. The Data were collected using information sheets, and then data was analyzed using (SPSS) v 24.0 Result: In this study the patients were equally distribution according to gender and 36% had advanced age, 49% had weight between 60 -80 kg,, 32% had diabetes mellitus and 16% had cerebrovascular disease, 31% of patients had repair of ankle fracture surgery, 29% had repair of femoral neck fracture and trochanteric fracture, hip replacement, 68% were used enoxaparin anticoagulant after surgery with dose 4000 IU, and only 32% of them used tinzaparin 4500 IU, 64% had duration of treatment between 1-2 weeks, 88% did (4000IU) and tinzaparin (4500IU) the most common type of LMWH were used for 1-2 not used anticoagulant after discharge. All of patients had no laboratory test while taking anticoagulant and had more than week of hospitalization. Conclusion: The study concluded that all of patients that used LMWH as anticoagulant prophylaxis. Enoxaparin (4000IU) and tinzaparin (4500IU) the most common type of LMWH that use for 1-2 weeks.